PCA
ABBV icon

Pallas Capital Advisors’s AbbVie ABBV Stock Holding History

Pallas Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.53M Sell
25,441
-2,588
-9% -$574K 0.21% 95
2025
Q4 		$6.4M Sell
28,029
-2,261
-7% -$515K 0.21% 85
2025
Q3 		$7.01M Sell
30,290
-1,019
-3% -$208K 0.26% 79
2025
Q2 		$5.81M Buy
31,309
+739
+2% +$137K 0.22% 83
2025
Q1 		$6.4M Buy
30,570
+706
+2% +$137K 0.27% 77
2024
Q4 		$5.31M Sell
29,864
-236
-0.8% -$43.4K 0.23% 89
2024
Q3 		$5.71M Sell
30,100
-291
-1% -$54.3K 0.24% 88
2024
Q2 		$5.2M Buy
30,391
+185
+0.6% +$30.6K 0.23% 93
2024
Q1 		$5.5M Buy
30,206
+3,374
+13% +$581K 0.23% 87
2023
Q4 		$4.16M Sell
26,832
-3,093
-10% -$451K 0.22% 93
2023
Q3 		$4.25M Buy
29,925
+6,729
+29% +$988K 0.26% 80
2023
Q2 		$3.13M Buy
23,196
+17,337
+296% +$2.54M 0.14% 93
2023
Q1 		$961K Buy
5,859
+2,305
+65% +$352K 0.09% 150
2022
Q4 		$532K Buy
3,554
+28
+0.8% +$4.29K 0.05% 177
2022
Q3 		$509K Buy
3,526
+31
+0.9% +$4.45K 0.06% 166
2022
Q2 		$519K Sell
3,495
-178
-5% -$27.2K 0.07% 143
2022
Q1 		$596K Buy
3,673
+1,202
+49% +$175K 0.08% 145
2021
Q4 		$326K Sell
2,471
-416
-14% -$49.1K 0.04% 243
2021
Q3 		$339K Sell
2,887
-288
-9% -$32.9K 0.04% 290
2021
Q2 		$365K Buy
3,175
+1,307
+70% +$147K 0.05% 229
2021
Q1 		$217K Buy
+1,868
New +$200K 0.05% 172

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Pallas Capital Advisors's ABBV Position: Q1 2026 in Review

Pallas Capital Advisors reduced its AbbVie (ABBV) stake by 9.2% in Q1 2026, selling an estimated $574K and leaving 25,441 shares worth $5.53M. The position accounts for 0.21% of the portfolio, ranked #95.

Pallas Capital Advisors first reported a position in ABBV in Q1 2021 and has held it in 21 quarters since. The position peaked at $7.01M in Q3 2025. 4,081 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Pallas Capital Advisors held 25,441 shares of AbbVie worth $5.53M as of Q1 2026.
  • Pallas Capital Advisors sold 2,588 AbbVie shares in Q1 2026, an estimated $574K.
  • AbbVie made up 0.21% of Pallas Capital Advisors's portfolio in Q1 2026, its #95 holding.
  • Pallas Capital Advisors first reported a position in AbbVie in Q1 2021 and has held it in 21 quarters since.
  • Pallas Capital Advisors's AbbVie position peaked at $7.01M in Q3 2025.
  • 4,081 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Pallas Capital Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.